Douglas W. Mapel, MD

home / authors / douglas-w-mapel-md

Articles

February 17th 2018

Claims-Based Risk Model for First Severe COPD Exacerbation

Richard H. Stanford, PharmD, MS Arpita Nag, PhD, MBA, MS Douglas W. Mapel, MD Todd A. Lee, PhD Richard Rosiello, MD Michael Schatz, MD Francis Vekeman, MS Marjolaine Gauthier-Loiselle, PhD J.F. Philip Merrigan, PhD Mei Sheng Duh, ScD

A health insurance claims-based risk assessment tool to predict patients’ first severe chronic obstructive pulmonary disease exacerbation has been developed and validated.

March 16th 2011

COPD-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenanc

Anand A. Dalal, PhD, MBA Manan Shah, PhD Anna O. D'Souza, PhD Douglas W. Mapel, MD

Initiation of fluticasone propionate–salmeterol after a COPD-related hospitalization or ED visit decreased the risk of a recurrent event and reduced COPD-related medical costs.

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: November 1st 2024 | Updated: November 21st 2024

Table Multiple Myeloma Trials November 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions